粪便菌群移植治疗免疫抑制患者复发性艰难梭菌感染的有效性与安全性
本系统综述与荟萃分析纳入44项研究共3476例受试者,其中1208例为免疫抑制患者,评估粪便菌群移植(FMT)治疗复发性艰难梭菌感染(rCDI)的效果。单次FMT临床缓解率为75.3%(95%CI 71.7%-78.6%),连续治疗升至87.4%(95%CI 84.8%-89.6%),复发率23.9%(95%CI 19.2%-29.4%),严重不良事件率10.1%(95%CI 6.7%-14.8%)。轻至中度免疫抑制患者的有效性与安全性结局与免疫正常人群相当。
要点
- 轻至中度免疫抑制患者接受FMT治疗rCDI的安全性和有效性与免疫正常人群相当。
- 单次FMT临床缓解率为75.3%,连续治疗可提高至87.4%。
- 复发率为23.9%,严重不良事件率为10.1%。
核心结论
- 在轻至中度免疫抑制人群中,FMT治疗rCDI的安全性和有效性与免疫正常人群相当。
研究设计与样本
- 系统综述与荟萃分析,检索Ovid MEDLINE、Ovid EMBASE、Clinicaltrials.gov和Scopus至2024年12月16日,纳入44项研究(31篇全文、13篇摘要),共3476例受试者,其中免疫抑制患者1208例。
- 免疫抑制人群包括实体器官移植受者219例、接受化疗的癌症患者101例、造血干细胞移植受者29例和晚期HIV患者11例。
- 采用随机效应模型进行统计分析以处理研究间异质性。
主要发现
- 单次FMT后临床缓解率为75.3%(95%CI 71.7%-78.6%),连续治疗后的临床缓解率为87.4%(95%CI 84.8%-89.6%)。
- 复发率为23.9%(95%CI 19.2%-29.4%),严重不良事件发生率为10.1%(95%CI 6.7%-14.8%)。
- 最常见的FMT给药途径为结肠镜(12项研究),其次为上消化道途径、胶囊和直肠保留灌肠。
临床怎么用
- 对于轻至中度免疫抑制的rCDI患者,FMT可作为治疗选择,其安全性和有效性预期与免疫正常人群相近。
局限性
- 纳入研究包含13篇会议摘要,可能影响数据完整性和质量。
- 免疫抑制亚组(如晚期HIV仅11例、造血干细胞移植受者仅29例)样本量较小,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Clostridioides difficile infection (CDI) poses a significant health risk to immunocompromised hosts due to the increased risk of severe infection and recurrence. Microbiota-based therapies have emerged as a promising strategy for CDI, but safety and efficacy in immunocompromised populations remain underexplored. METHODS: A comprehensive literature search across Ovid MEDLINE, Ovid EMBASE, Clinicaltrials.gov, and Scopus from inception until December 16, 2024, identified studies meeting inclusion criteria, covering fecal microbiota transplantation (FMT) for recurrent CDI (rCDI) in immunocompromised individuals, including those on immunosuppressants, transplant recipients, undergoing chemotherapy, and with advanced HIV. Case reports and studies not separately reporting outcomes in immunocompromised patients were excluded. Statistical analysis was performed using random-effects models to account for heterogeneity among studies. RESULTS: A total of 44 studies (31 full-text articles, 13 abstracts) were included, comprising 3476 participants, of whom 1208 were immunocompromised. The population included solid organ transplant recipients (n = 219), patients with cancer on chemotherapy (n = 101), hematopoietic stem cell transplant recipients (n = 29), and advanced HIV patients (n = 11). The most common FMT route was colonoscopy (n = 12 studies), followed by upper gastrointestinal routes, capsules, and rectal retention enemas. The clinical resolution rate after a single FMT was 75.3% (95% confidence interval [CI], 71.7%-78.6%), increasing to 87.4% (95% CI, 84.8%-89.6%) with consecutive treatments. The recurrence rate was 23.9% (95% CI, 19.2%-29.4%), and the serious adverse event rate was 10.1% (95% CI, 6.7%-14.8%). CONCLUSIONS: The safety and effectiveness outcomes of FMT in mild to moderately immunocompromised populations for rCDI are comparable to those in immunocompetent cohorts.
引用
- Berry P, Tariq R, Pardi DS, et al. Effectiveness and Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Immunocompromised Patients. Clin Gastroenterol Hepatol. 2025. PMID: 40759389. doi:10.1016/j.cgh.2025.06.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。